| Dr Robert T Tsuji, MD | |
|
206 S Hays St, Bel Air, MD 21014-4339 | |
| (410) 515-1515 | |
| (410) 900-1901 |
| Full Name | Dr Robert T Tsuji |
|---|---|
| Gender | Male |
| Speciality | Interventional Pain Management |
| Experience | 31 Years |
| Location | 206 S Hays St, Bel Air, Maryland |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1093758419 | NPI | - | NPPES |
| 403213600 | Medicaid | MD | |
| CA8374 | Other | MD | R/R MEDICARE GROUP # |
| P00119832 | Other | MD | R/R MEDICARE PROVIDER # |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208100000X | Physical Medicine & Rehabilitation | D60750 (Maryland) | Primary |
| 2081P2900X | Physical Medicine & Rehabilitation - Pain Medicine | D60750 (Maryland) | Secondary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Advanced Spine And Pain Centers, Pllc | 6709269327 | 10 |
News Archive
Taro Pharmaceutical Industries Ltd. announced that it has been granted an Investigational New Drug ("IND") exemption by the United States Food and Drug Administration, ("FDA"), to permit clinical studies on T2000 (1,3-dimethoxymethyl-5,5-diphenyl-barbituric acid), one of a class of non-sedating barbiturate compounds currently in development by the Company.
You may think a little white lie about a bad haircut is strictly for your friend's benefit, but your brain activity says otherwise. Distinct activity patterns in the prefrontal cortex reveal when a white lie has selfish motives, according to new research published in JNeurosci.
A relatively simple and inexpensive method may be used to determine whether a lung cancer patient is a candidate for crizotinib therapy, according to research published in the August issue of the Journal of Thoracic Oncology, the official monthly journal of the International Association for the Study of Lung Cancer.
EUSA Pharma, a transatlantic specialty pharmaceutical company focused on oncology, oncology supportive care and critical care, today announced that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ERWINASE(R) (L-asparaginase derived from Erwinia chrysanthemi) for use in the treatment of acute lymphoblastic leukemia in patients with hypersensitivity to E. coli-derived asparaginase.
› Verified 5 days ago
| Entity Name | Ritu Bhambhani Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1316133457 PECOS PAC ID: 3274608799 Enrollment ID: O20080819000250 |
News Archive
Taro Pharmaceutical Industries Ltd. announced that it has been granted an Investigational New Drug ("IND") exemption by the United States Food and Drug Administration, ("FDA"), to permit clinical studies on T2000 (1,3-dimethoxymethyl-5,5-diphenyl-barbituric acid), one of a class of non-sedating barbiturate compounds currently in development by the Company.
You may think a little white lie about a bad haircut is strictly for your friend's benefit, but your brain activity says otherwise. Distinct activity patterns in the prefrontal cortex reveal when a white lie has selfish motives, according to new research published in JNeurosci.
A relatively simple and inexpensive method may be used to determine whether a lung cancer patient is a candidate for crizotinib therapy, according to research published in the August issue of the Journal of Thoracic Oncology, the official monthly journal of the International Association for the Study of Lung Cancer.
EUSA Pharma, a transatlantic specialty pharmaceutical company focused on oncology, oncology supportive care and critical care, today announced that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ERWINASE(R) (L-asparaginase derived from Erwinia chrysanthemi) for use in the treatment of acute lymphoblastic leukemia in patients with hypersensitivity to E. coli-derived asparaginase.
› Verified 5 days ago
| Entity Name | Advanced Spine And Pain Centers, Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1982318929 PECOS PAC ID: 6709269327 Enrollment ID: O20220815003030 |
News Archive
Taro Pharmaceutical Industries Ltd. announced that it has been granted an Investigational New Drug ("IND") exemption by the United States Food and Drug Administration, ("FDA"), to permit clinical studies on T2000 (1,3-dimethoxymethyl-5,5-diphenyl-barbituric acid), one of a class of non-sedating barbiturate compounds currently in development by the Company.
You may think a little white lie about a bad haircut is strictly for your friend's benefit, but your brain activity says otherwise. Distinct activity patterns in the prefrontal cortex reveal when a white lie has selfish motives, according to new research published in JNeurosci.
A relatively simple and inexpensive method may be used to determine whether a lung cancer patient is a candidate for crizotinib therapy, according to research published in the August issue of the Journal of Thoracic Oncology, the official monthly journal of the International Association for the Study of Lung Cancer.
EUSA Pharma, a transatlantic specialty pharmaceutical company focused on oncology, oncology supportive care and critical care, today announced that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ERWINASE(R) (L-asparaginase derived from Erwinia chrysanthemi) for use in the treatment of acute lymphoblastic leukemia in patients with hypersensitivity to E. coli-derived asparaginase.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Robert T Tsuji, MD 206 S Hays St, Bel Air, MD 21014-3672 Ph: (410) 515-1515 | Dr Robert T Tsuji, MD 206 S Hays St, Bel Air, MD 21014-4339 Ph: (410) 515-1515 |
News Archive
Taro Pharmaceutical Industries Ltd. announced that it has been granted an Investigational New Drug ("IND") exemption by the United States Food and Drug Administration, ("FDA"), to permit clinical studies on T2000 (1,3-dimethoxymethyl-5,5-diphenyl-barbituric acid), one of a class of non-sedating barbiturate compounds currently in development by the Company.
You may think a little white lie about a bad haircut is strictly for your friend's benefit, but your brain activity says otherwise. Distinct activity patterns in the prefrontal cortex reveal when a white lie has selfish motives, according to new research published in JNeurosci.
A relatively simple and inexpensive method may be used to determine whether a lung cancer patient is a candidate for crizotinib therapy, according to research published in the August issue of the Journal of Thoracic Oncology, the official monthly journal of the International Association for the Study of Lung Cancer.
EUSA Pharma, a transatlantic specialty pharmaceutical company focused on oncology, oncology supportive care and critical care, today announced that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ERWINASE(R) (L-asparaginase derived from Erwinia chrysanthemi) for use in the treatment of acute lymphoblastic leukemia in patients with hypersensitivity to E. coli-derived asparaginase.
› Verified 5 days ago
John Everett Wilson, D..O Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 4 C North Ave, Suite 425, Bel Air, MD 21014 Phone: 410-838-8991 Fax: 410-838-0727 | |
Kevin W. Bedwell, PA-C Physical Medicine & Rehabilitation Medicare: Medicare Enrolled Practice Location: 2012 S Tollgate Rd Ste 207, Bel Air, MD 21015 Phone: 443-371-9750 Fax: 443-371-9751 |